A comparative analysis of treatment of hyperphosphatemia with Sevelamer hydrochloride vs calcium acetate in hemodialysis patients

被引：0
|
作者：
Khalid, F
Shafi, M
Siddiqi, N
Ali, Y
机构：
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
76
引用
收藏
页码：A37 / A37
页数：1
相关论文
共 50 条
  • [1] Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients:: A comparison with calcium acetate
    Hervás, JG
    Prados, D
    Cerezo, S
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S69 - S72
  • [2] A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
    Bleyer, AJ
    Burke, SK
    Dillon, M
    Garrett, B
    Kant, KS
    Lynch, D
    Rahman, SN
    Schoenfeld, P
    Teitelbaum, I
    Zeig, S
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) : 694 - 701
  • [3] Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan
    Koiwa, F
    Onoda, N
    Kato, H
    Tokumoto, A
    Okada, T
    Fukagawa, M
    Shigematsu, T
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (04) : 340 - 346
  • [4] A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients
    Liu, Yao-Lung
    Lin, Hsin-Hung
    Yu, Chun-Chen
    Kuo, Huey-Liang
    Yang, Ya-Fei
    Chou, Che-Yi
    Lin, Po-Wen
    Liu, Jiung-Hsiun
    Liao, Pen-Yuan
    Huang, Chiu-Ching
    [J]. RENAL FAILURE, 2006, 28 (08) : 701 - 707
  • [5] Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia
    Akizawa, Tadao
    Origasa, Hideki
    Kameoka, Chisato
    Kaneko, Yuichiro
    Kawasaki, Shigenori
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 (02) : 122 - 131
  • [6] Comparative Efficacy of Sevelamer Hydrochloride Versus Calcium Acetate on Bone Biomarkers in patients with End Stage Renal Disease on Hemodialysis
    Ahmed, Waqar
    Rizwan-UL-Haq
    Akram, Mateen
    Khan, Sami
    Haider, Saqlain
    Abad-UR-Rehman
    [J]. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2014, 8 (03): : 769 - 771
  • [7] A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients
    Chertow, GM
    Dillon, M
    Burke, SK
    Steg, M
    Bleyer, AJ
    Garrett, BN
    Domoto, DT
    Wilkes, BM
    Wombolt, DG
    Slatopolsky, E
    [J]. CLINICAL NEPHROLOGY, 1999, 51 (01) : 18 - 26
  • [8] Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
    Wang, Yong
    Xie, Guoqiang
    Huang, Yuanhang
    Zhang, Han
    Yang, Bo
    Mao, Zhiguo
    [J]. PLOS ONE, 2015, 10 (03):
  • [9] Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients
    Iwasaki, Y
    Takami, H
    Tani, M
    Yamaguchi, Y
    Goto, H
    Goto, Y
    Goto, Y
    Shigematsu, T
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (04) : 347 - 351
  • [10] Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE study)
    Qunibi, WY
    Hootkins, RE
    McDowell, LL
    Meyer, MS
    Simon, M
    Garza, RO
    Pelham, RW
    Cleveland, MVB
    Muenz, LR
    He, DY
    Nolan, CR
    [J]. KIDNEY INTERNATIONAL, 2004, 65 (05) : 1914 - 1926
12345